权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Project 2: Enhancing Efficacy of Gemcitabine Nanoparticles in Pancreatic PDX Models

项目2：增强吉西他滨纳米颗粒在胰腺PDX模型中的功效

基本信息

批准号：
10006118
负责人：
BO HAN
金额：
$ 9.58万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-19 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10006118
关键词：
3-Dimensional Affect Animal Model Antineoplastic Agents Biological Biopsy Blood Breast California Cancer Etiology Cancer Patient Carcinoma Caucasians Cessation of life Characteristics Chemosensitization Chemotherapy and/or radiation Classification Clinical Clinical Trials Colon Cytidine Deaminase DNA Data Detection Diagnosis Disease Drug Delivery Systems Drug Kinetics Drug usage Early Diagnosis Education Effectiveness Enzymes Epidermal Growth Factor Receptor Erlotinib Fc Receptor Fingers Florida Fluorouracil Genetic Growth Health High Prevalence Human Hyaluronan Hyaluronidase Incidence Individual Investigation Knowledge Latino Link Liver Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of pancreas Malignant neoplasm of prostate Mediating Methods Molecular Molecular Profiling Mutation Analysis Nature Operative Surgical Procedures Paclitaxel Pancreas Pathway interactions Patient-Focused Outcomes Patients Pharmaceutical Preparations Play Prostate Publishing RRM1 gene Rectal Cancer Regimen Reporting Resected Resistance Surface Survival Rate Symptoms Testing Therapeutic Tissues Translating Treatment Efficacy Underrepresented Minority Woman Xenograft Model amino group anticancer research base cancer cell cancer diagnosis cancer genome cancer health disparity capecitabine chemotherapeutic agent chemotherapy cytotoxicity design experience experimental study gemcitabine health equity improved in vitro activity in vivo malignant breast neoplasm men mortality nanoparticle neoplastic cell novel anticancer drug novel therapeutics overexpression pancreas xenograft pancreatic cancer patients pancreatic neoplasm personalized approach personalized therapeutic response screening therapeutic target therapy resistant tool treatment response tripolyphosphate tumor

项目摘要

PROJECT SUMMARY/ABSTRACT: FULL PROJECT 2 Pancreatic Cancer (PCa) is a devastating disease for all affected. Presently, PCa is the 3rd leading cause of cancer-related death in the U.S. The five-year overall survival rate is a dismal 7.2%. While PCa has not be recorded as a cancer health disparity, the data is quite alarming, for example, Blacks experience a higher prevalence of compared to their Whites. Moreover, Black men and women have the lowest overall survival rates of PCa. Interestingly, while many cancers have demonstrated a reduction in incidence over a 5-year period (2008-2012), the incidence and number of deaths from PCa are projected to significantly increase among Blacks nationwide, further fingering PCa as a cancer health disparity. Additionally, although we have seen significant improvements in overall survival for prostate, breast, and colon/rectal cancer, PCa is projected to be the second leading cause of cancer deaths by 2030. Presently, there are no screening tests for PCa and early diagnosis is difficult because PCa often develops without any symptoms and indications are nonspecific. Thus there is a need, novel anticancer drug delivery that will enhance the efficacy of existing drugs, such as Gemcitabine for use to improve PCa patient outcomes. This collaborative study proposes to investigate critical barriers to PCa therapeutics and also define a more personalized therapeutic approach for underrepresented minority PCa patients. We will identify molecular charateristics that help differentiate molecular signature between pancreatic tumors among Blacks and Latinos which will allow for a more personalized approach to targeting PCa. We plan to design and develop stearoyl-linked-Gemcitabine with surface modified anti-EGFR antibody nanoparticles (GemEnps); evaluate GemEnps as a potential alternative chemotherapeutic agent in the treatment of PCa orthotopic PDX pancreatic animal models based on the similarities and differences in sequencing of pancreatic cancer genomes of Blacks, Latinos and Whites and translate knowledge of DNA changes to clinical tools for better management of Black and Latino with PCa.

项目摘要/摘要：完整项目2